Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

FOPO nets $282mm for Amicus

Executive Summary

Amicus Therapeutics Inc. (therapies for rare metabolic conditions) netted $282mm in its follow-on public offering of 19.35mm common shares at $15.50. The company will use some of the proceeds for global commercialization of migalastat for Fabry's disease, to invest in manufacturing capabilities for its Phase II Pompe disease candidate ATB200, and for additional R&D and commercial activities.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies